All abstracts

All Posters

Topics

Presentation Type

Loading

Clear all filters

Return to work after major depressive disorder: predictive factors and reintegration strategies

Occupational Determinants of Depression Severity among Healthcare Workers: Insights from a 12-Year Study

Does Intranasal Esketamine Show Differential Efficacy with SSRIs versus SNRIs in Treatment-Resistant Depression?

Endogenous Lithium Status in Major Depression: A Retrospective Analysis of EDTA Blood Samples

Prevalence of Anxiety-Depressive Disorders and Stress Among Administrative Staff

Assessing Mental Health: Depressive Disorders among Healthcare Workers During Pre-Employment Evaluations

Forgiveness, dignity and hopelessness: the role of mediation and balance in MDD

App-supported Intervention for Digital Aftercare to Bridge Long Waiting Periods between Inpatient and Outpatient Treatment of Depression

What happens after stopping IN Esketamine? A prospective report of case series

Beyond the Block: Cariprazine in Treatment-Resistant Depression

Case-study: Patient with second depressive episode and catatonia

Aripiprazole and Brexpiprazole as Adjunctive Therapies for Difficult-to-Treat Depression: A Literature Review of Clinical Effectiveness, Safety, and Cost-Effectiveness

Invisible Emergency: Stress and Anxiety-Depressive Disorders among Medical Students in Tunisia

Anxiety and Depressive Disorders in Chronic Hemodialysis Patients

Short-term preliminary clinical results from HIPOCRAT-ESK study: a cohort, non-interventional, prospective, real-world study of functional remission in TRD patients treated with Esketamina nasal spray.

Short-term preliminary PROs results from HIPOCRAT-ESK study: a cohort, non-interventional, prospective, real-world study of functional remission in TRD patients treated with Esketamina nasal spray

EEG dynamics during treatment in elderly depressive patients with organic mood disorder

EEG features in depressive patients with high and low levels of aggressiveness

EEG correlates of anxiety in young female depressive patients

Illness course variables as predictors of efficacy and speed of response to Spravaro in major depressive disorder